Telisotuzumab vedotin

Telisotuzumab vedotin (ABBV-399) is an antibody-drug conjugate (ADCs) targeting c-Met. Telisotuzumab vedotin consists of Monomethyl Auristatin E (MMAE), Telisotuzumab antibody and a cleavable mc-val-cit-PABC type linker. Telisotuzumab vedotin can be used to study non-small cell lung cancer expressing c-Met protein[1][2].

Product Specifications

CAS Number

[1714088-51-3]

Product Name Alternative

ABBV-399

UNSPSC

12352203

Target

Antibody-Drug Conjugates (ADCs) ; c-Met/HGFR

Type

ADC Related

Related Pathways

Antibody-drug Conjugate/ADC Related; Protein Tyrosine Kinase/RTK

Applications

Cancer-Kinase/protease

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/telisotuzumab-vedotin.html

Purity

99.81

Solubility

DMSO : ≥ 100 mg/mL

Smiles

[Telisotuzumabvedotin]

Molecular Weight

145000 (average)

References & Citations

[1]Strickler JH, et al. First-in-Human Phase I, Dose-Escalation and -Expansion Study of Telisotuzumab Vedotin, an Antibody-Drug Conjugate Targeting c-Met, in Patients With Advanced Solid Tumors. J Clin Oncol. 2018 Nov 20;36 (33) :3298-3306. |[2]Camidge D R, et al. Phase Ib study of telisotuzumab vedotin in combination with erlotinib in patients with c-met protein–expressing non–small-cell lung cancer. Journal of Clinical Oncology, 2023, 41 (5) : 1105-1115.